<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762851</url>
  </required_header>
  <id_info>
    <org_study_id>RCT-IVVE 2015</org_study_id>
    <nct_id>NCT02762851</nct_id>
  </id_info>
  <brief_title>Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)</brief_title>
  <acronym>RCT-IVVE</acronym>
  <official_title>A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centre, randomized, placebo controlled, trial. Participants at high-risk for vascular
      events from the network of INTER- CHF will be randomized to inactivated influenza vaccine or
      placebo and followed prospectively over three influenza seasons. 5,000 participants will be
      enrolled prior to influenza season, randomized to either influenza vaccine or saline placebo,
      either of which they will receive annually for three years and then followed over each of the
      influenza seasons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is a major cause of morbidity and mortality. There is recent evidence
      that infection due to influenza may precipitate vascular events such as myocardial
      infarctions and strokes. There is some evidence that influenza vaccination may prevent such
      events but the data are inconclusive. The investigators propose a randomized controlled trial
      to assess whether influenza vaccination will prevent vascular illness. Adults with clinical
      heart failure will be randomized to inactivated influenza vaccine or saline placebo each year
      for three consecutive years. They will be followed over six months for a composite of
      cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalizations
      for heart failure using standardized criteria. Rigorous demonstration of influenza vaccine
      leading to a reduction in major adverse vascular events in patients with heart failure would
      lead to a major change in how these patients are managed. Given the large burden of disease
      both in Canada and globally, the possibility to reduce cardiovascular and stroke related
      death is a compelling reason to conduct this trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse cardiovascular event</measure>
    <time_frame>Six months</time_frame>
    <description>The primary outcome will be a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalizations for heart failure using standardized criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular (CV) death</measure>
    <time_frame>Six months</time_frame>
    <description>CV death alone will be a secondary outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Heart Failure</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine prior to the influenza season.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants at high risk for adverse vascular events will be vaccinated with a 0.5 ml dose of sterile saline prior to the influenza season.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sterile saline</intervention_name>
    <description>0.5 ml dose injected intramuscularly</description>
    <arm_group_label>Placebo vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inactivated trivalent influenza vaccine</intervention_name>
    <description>0.5 ml dose injected intramuscularly</description>
    <arm_group_label>Influenza vaccine</arm_group_label>
    <other_name>VAXIGRIP vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years and NYHA (New York Heart Association) functional class II, III and IV

        Exclusion Criteria:

          -  Anaphylactic reaction to a previous dose of TIV(trivalent influenza vaccine)

          -  Known IgE( Immunoglobulin E)-mediated hypersensitivity to eggs manifested as hives,
             swelling of the mouth and throat, difficulty in breathing, hypotension, or shock

          -  Guillain-Barré syndrome within eight weeks of a previous influenza vaccine

          -  Anaphylactic reaction to neomycin

          -  Patients who have had influenza vaccine in two of the three previous years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Loeb, MD, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Loeb, MD, MSc.</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>26066</phone_ext>
    <email>loebm@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Douala General Hospital</name>
      <address>
        <city>Douala</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Xicheng District</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Liang, MD</last_name>
      <email>yan.liang@phri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jun Zhu, MD</last_name>
      <email>junzhuld@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre for Chronic Disease Control</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorairaj Prabhakaran, MD</last_name>
      <email>dprabhakaran@ccdcindia.org</email>
    </contact>
    <investigator>
      <last_name>Ambuj Roy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Yonga, MD</last_name>
      <email>gerald.yonga@aku.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marwan Refaat, MD</last_name>
      <phone>+961-1-350000</phone>
      <phone_ext>5825</phone_ext>
      <email>mr48@aub.edu.lb</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maputo Central Hospital (Full Trial)</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albertino Damasceno, MD</last_name>
      <phone>258 2131 0828</phone>
      <email>tino_7117@yahoo.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bayero University and Aminu Kano Teaching Hospital</name>
      <address>
        <city>Kano</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamilu Karaye, MD</last_name>
      <phone>234 803 704 2171</phone>
      <email>kkaraye@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Philippines</name>
      <address>
        <city>Manila</city>
        <state>Emita</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia Palileo, MD</last_name>
      <email>liapalileo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Dans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Saud Univeristy</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalid Al-Habib, MD</last_name>
      <phone>966 1 288 9999</phone>
      <email>khalidalhabib13@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AlShaab Teaching Hospital</name>
      <address>
        <city>Khartoum</city>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Mulago Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Mondo, MD</last_name>
      <phone>256 772 462370</phone>
      <email>charles_mondo@yahoo.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheikh Khalifa Medical City</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wael Almahmeed, MD</last_name>
      <email>wmahmeed@emirates.net.ae</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Zambia School of Medicine</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fastone Goma, MD</last_name>
      <email>gomafm@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>China</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Lebanon</country>
    <country>Mozambique</country>
    <country>Nigeria</country>
    <country>Philippines</country>
    <country>Saudi Arabia</country>
    <country>Sudan</country>
    <country>Uganda</country>
    <country>United Arab Emirates</country>
    <country>Zambia</country>
  </location_countries>
  <reference>
    <citation>Causes of death 2008, World Health Organization, Geneva, http://www.who.int/healthinfo/ global_burden_disease/ cod_2008_sources_methods.pdf.</citation>
  </reference>
  <reference>
    <citation>Statistics Canada. Morality, Summary List of Causes 2008. Released October 18, 2011.</citation>
  </reference>
  <reference>
    <citation>Tracking Heart Disease and Stroke in Canada. Released June 2009</citation>
  </reference>
  <reference>
    <citation>Remme WJ, Torp-Pedersen C, Cleland JG, Poole-Wilson PA, Metra M, Komajda M, Swedberg K, Di Lenarda A, Spark P, Scherhag A, Moullet C, Lukas MA. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol. 2007 Mar 6;49(9):963-71. Epub 2007 Feb 20.</citation>
    <PMID>17336720</PMID>
  </reference>
  <reference>
    <citation>Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: JAMA. 2013 Apr 10;309(14):1461.</citation>
    <PMID>23478743</PMID>
  </reference>
  <reference>
    <citation>Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11.</citation>
    <PMID>19001508</PMID>
  </reference>
  <reference>
    <citation>Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010 Dec 11;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadán, I Roldan]; Leva, M [corrected to Ieva, M].</citation>
    <PMID>20801500</PMID>
  </reference>
  <reference>
    <citation>Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012 May 17;366(20):1859-69. doi: 10.1056/NEJMoa1202299. Epub 2012 May 2.</citation>
    <PMID>22551105</PMID>
  </reference>
  <reference>
    <citation>Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997 Nov 6;80(9A):11I-16I. Review.</citation>
    <PMID>9375937</PMID>
  </reference>
  <reference>
    <citation>Chan NN, Colhoun HM, Vallance P. Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. J Am Coll Cardiol. 2001 Dec;38(7):1814-20.</citation>
    <PMID>11738279</PMID>
  </reference>
  <reference>
    <citation>Davies MJ. The composition of coronary-artery plaques. N Engl J Med. 1997 May 1;336(18):1312-4.</citation>
    <PMID>9113937</PMID>
  </reference>
  <reference>
    <citation>Wanishsawad C, Zhou YF, Epstein SE. Chlamydia pneumoniae-induced transactivation of the major immediate early promoter of cytomegalovirus: potential synergy of infectious agents in the pathogenesis of atherosclerosis. J Infect Dis. 2000 Feb;181(2):787-90.</citation>
    <PMID>10669378</PMID>
  </reference>
  <reference>
    <citation>Conti CR. Vascular events responsible for thrombotic occlusion of a blood vessel. Clin Cardiol. 1993 Nov;16(11):761-2.</citation>
    <PMID>8269651</PMID>
  </reference>
  <reference>
    <citation>Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation. 1997 Nov 18;96(10):3266-8.</citation>
    <PMID>9396413</PMID>
  </reference>
  <reference>
    <citation>Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999 Jul;34(1):146-54.</citation>
    <PMID>10400004</PMID>
  </reference>
  <reference>
    <citation>Gwini SM, Coupland CA, Siriwardena AN. The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. Vaccine. 2011 Feb 1;29(6):1145-9. doi: 10.1016/j.vaccine.2010.12.017. Epub 2010 Dec 18.</citation>
    <PMID>21172383</PMID>
  </reference>
  <reference>
    <citation>Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000 Dec 19;102(25):3039-45.</citation>
    <PMID>11120692</PMID>
  </reference>
  <reference>
    <citation>Meyers D, Beahm D, Jurisich P, Milford C, Edlavich S. Influenza and pneumococcal vaccinations fail to prevent myocardial infarction. Heart Drug. 2004;4:96 -100.</citation>
  </reference>
  <reference>
    <citation>Lavallée P, Perchaud V, Gautier-Bertrand M, Grabli D, Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. Stroke. 2002 Feb;33(2):513-8. Erratum in: Stroke 2002 Apr;33(4):1171.</citation>
    <PMID>11823662</PMID>
  </reference>
  <reference>
    <citation>Siscovick DS, Raghunathan TE, Lin D, Weinmann S, Arbogast P, Lemaitre RN, Psaty BM, Alexander R, Cobb LA. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol. 2000 Oct 1;152(7):674-7.</citation>
    <PMID>11032163</PMID>
  </reference>
  <reference>
    <citation>Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ. 2010 Oct 19;182(15):1617-23. doi: 10.1503/cmaj.091891. Epub 2010 Sep 20.</citation>
    <PMID>20855479</PMID>
  </reference>
  <reference>
    <citation>Heffelfinger JD, Heckbert SR, Psaty BM, Weiss NS, Thompson WW, Bridges CB, Jackson LA. Influenza vaccination and risk of incident myocardial infarction. Hum Vaccin. 2006 Jul-Aug;2(4):161-6. Epub 2006 Jul 24.</citation>
    <PMID>17012887</PMID>
  </reference>
  <reference>
    <citation>Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003 Apr 3;348(14):1322-32.</citation>
    <PMID>12672859</PMID>
  </reference>
  <reference>
    <citation>Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW; Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol. 2002 Oct 1;156(7):634-40.</citation>
    <PMID>12244032</PMID>
  </reference>
  <reference>
    <citation>Armstrong BG, Mangtani P, Fletcher A, Kovats S, McMichael A, Pattenden S, Wilkinson P. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ. 2004 Sep 18;329(7467):660. Epub 2004 Aug 15.</citation>
    <PMID>15313884</PMID>
  </reference>
  <reference>
    <citation>Wang CS, Wang ST, Lai CT, Lin LJ, Chou P. Impact of influenza vaccination on major cause-specific mortality. Vaccine. 2007 Jan 26;25(7):1196-203. Epub 2006 Oct 25.</citation>
    <PMID>17097773</PMID>
  </reference>
  <reference>
    <citation>Johnstone J, Loeb M, Teo KK, Gao P, Dyal L, Liu L, Avezum A, Cardona-Munoz E, Sleight P, Fagard R, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global EndPoint Trial (ONTARGET); Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation. 2012 Jul 17;126(3):278-86. doi: 10.1161/CIRCULATIONAHA.111.071100. Epub 2012 Jun 19.</citation>
    <PMID>22715472</PMID>
  </reference>
  <reference>
    <citation>Keller T, Weeda VB, van Dongen CJ, Levi M. Influenza vaccines for preventing coronary heart disease. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005050. doi: 10.1002/14651858.CD005050.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;5:CD005050.</citation>
    <PMID>18646119</PMID>
  </reference>
  <reference>
    <citation>Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009 Oct;9(10):601-10. doi: 10.1016/S1473-3099(09)70233-6. Review.</citation>
    <PMID>19778762</PMID>
  </reference>
  <reference>
    <citation>Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23;310(16):1711-20. doi: 10.1001/jama.2013.279206.</citation>
    <PMID>24150467</PMID>
  </reference>
  <reference>
    <citation>Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011 Jul;32(14):1730-5. doi: 10.1093/eurheartj/ehr004. Epub 2011 Feb 2.</citation>
    <PMID>21289042</PMID>
  </reference>
  <reference>
    <citation>Natarajan P, Cannon CP. Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention. Eur Heart J. 2011 Jul;32(14):1701-3. doi: 10.1093/eurheartj/ehr053. Epub 2011 Mar 15.</citation>
    <PMID>21406438</PMID>
  </reference>
  <reference>
    <citation>Canadian Communicable Disease Report 2012. Statement on seasonal influenza vaccine for 2012-2013; 38: 2012.</citation>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2012 Aug 17;61(32):613-8.</citation>
    <PMID>22895385</PMID>
  </reference>
  <reference>
    <citation>Blank PR, Schwenkglenks M, Szucs TD. Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons. Infection. 2009 Oct;37(5):390-400. doi: 10.1007/s15010-009-8467-y. Epub 2009 Sep 18.</citation>
    <PMID>19768382</PMID>
  </reference>
  <reference>
    <citation>Mereckiene J, Cotter S, Nicoll A, Levy-Bruhl D, Ferro A, Tridente G, Zanoni G, Berra P, Salmaso S, O'Flanagan D, O Flanagan D; VENICE Project Gatekeepers Group. National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill. 2008 Oct 23;13(43). pii: 19017.</citation>
    <PMID>18947524</PMID>
  </reference>
  <reference>
    <citation>Population Health Research Institute http://www.phri.ca/</citation>
  </reference>
  <reference>
    <citation>ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.</citation>
    <PMID>22686416</PMID>
  </reference>
  <reference>
    <citation>ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.</citation>
    <PMID>22686415</PMID>
  </reference>
  <reference>
    <citation>ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.</citation>
    <PMID>21366473</PMID>
  </reference>
  <reference>
    <citation>CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010 Sep 2;363(10):930-42. doi: 10.1056/NEJMoa0909475. Erratum in: N Engl J Med. 2010 Oct 14;363(16):1585.</citation>
    <PMID>20818903</PMID>
  </reference>
  <reference>
    <citation>ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.</citation>
    <PMID>20228404</PMID>
  </reference>
  <reference>
    <citation>ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.</citation>
    <PMID>20228401</PMID>
  </reference>
  <reference>
    <citation>Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.</citation>
    <PMID>18539917</PMID>
  </reference>
  <reference>
    <citation>DataFax - Data Management Software for Clinical Trials. http://www.datafax.com/; accessed February 15, 2013.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Vascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

